About this episode

Michael Levy and Peter Sguigna discuss the implications of the METEOROID trial results for MOGAD management.

No Label: Michael Levy, MD, PhD No Label: Peter V. Sguigna, MD What do the latest METEOROID trial results mean for neurologists treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)? Michael Levy, MD, Massachusetts General Hospital, Boston, MA, discusses relapse prevention, diagnostic challenges, and the future of MOGAD management with Peter Sguigna, MD, UT Southwestern Medical Center, Dallas, TX.

More episodes of NeuroFrontiers

• Multidisciplinary Coordination in TK2d Diagnosis and Management · June 24, 2026 · 11 min

Explore listener stats, chart rankings, contacts and more on the NeuroFrontiers podcast page.